Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eduardo Forleo-Neto

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Open Forum Infectious Diseases|July 7, 2023
A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2Elizabeth R Brown, Meagan P O'Brien, Brian Snow, et al.
The Pediatric Infectious Disease Journal|July 19, 2014
Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of ageLuisanna Zedda, Eduardo Forleo-Neto, André Vertruyen, et al.
Emerging Infectious Diseases|June 18, 2004
Antigenic and genetic variability of human metapneumovirusesBernadette G van den Hoogen, Sander Herfst, Leo Sprong, et al.
Vaccine|September 17, 2014
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young childrenTerry Nolan, Lulu Bravo, Ana Ceballos, et al.
Open Forum Infectious Diseases|December 19, 2023
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 InfectionMeng Xu, Meagan P O'Brien, Andrea T Hooper, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 8, 2020
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm InfantsEric A F Simões, Eduardo Forleo-Neto, Gregory P Geba, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Open Forum Infectious Diseases|July 7, 2023
A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2Elizabeth R Brown, Meagan P O'Brien, Brian Snow, et al.
The Pediatric Infectious Disease Journal|July 19, 2014
Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of ageLuisanna Zedda, Eduardo Forleo-Neto, André Vertruyen, et al.
Emerging Infectious Diseases|June 18, 2004
Antigenic and genetic variability of human metapneumovirusesBernadette G van den Hoogen, Sander Herfst, Leo Sprong, et al.
Vaccine|September 17, 2014
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young childrenTerry Nolan, Lulu Bravo, Ana Ceballos, et al.
Open Forum Infectious Diseases|December 19, 2023
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 InfectionMeng Xu, Meagan P O'Brien, Andrea T Hooper, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 8, 2020
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm InfantsEric A F Simões, Eduardo Forleo-Neto, Gregory P Geba, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Pageof 3